The ATOX1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This heterogeneous cell pool carries targeted disruptions of the ATOX1 gene, creating a loss-of-function model for studying copper chaperone biology. The polyclonal format offers a robust population-level knockout without the need for single-cell cloning, facilitating consistent experimental performance. Gene disruption is verified at the protein level, and the cells exhibit impaired copper trafficking, making them suitable for investigating copper homeostasis and related signaling in a lung adenocarcinoma context.
The A-549 cell line, originally established from the lung adenocarcinoma tissue of a 58-year-old Caucasian male, is a widely employed model for cancer research and respiratory studies. As a type II alveolar epithelial cell line, A-549 retains characteristics relevant to the alveolar epithelium and is frequently used to investigate oncogenic signaling, drug responses, and metabolic dysregulation in non-small cell lung cancer. Its adherent growth and robust experimental tractability further support its utility for high-throughput assays and mechanistic studies.
ATOX1 encodes a cytosolic copper chaperone that transfers copper ions to ATP7A and ATP7B, enabling copper incorporation into essential cuproenzymes such as SOD1, COX, lysyl oxidase, tyrosinase, and ceruloplasmin. ATOX1 is transcriptionally regulated by Sp1 and responds to copper availability and oxidative stress. It acts upstream of ATP7A/B and interacts with these ATPases and with CCS to coordinate copper trafficking. Key pathway components include CTR1, ATOX1, ATP7A/B, SOD1, CCS, ceruloplasmin, and metallothioneins. ATOX1 disruption impairs copper delivery to these enzymes, diminishing enzymatic activity and altering redox balance.
In the context of A-549 lung adenocarcinoma cells, ATOX1 knockout provides a system to dissect the role of copper chaperoning in tumor biology. Copper is critical for oncogenic processes, including angiogenesis, proliferation, and metastasis, and copper-dependent enzymes such as SOD1 and COX are often dysregulated in cancer. Loss of ATOX1 disrupts copper trafficking, which can attenuate the activity of these enzymes and sensitize cells to oxidative stress. This model enables the exploration of copper-related vulnerabilities in lung adenocarcinoma and supports the identification of therapeutic targets.
Research applications include investigating copper homeostasis and trafficking in lung adenocarcinoma, analyzing ATOX1-dependent activation of copper-dependent enzymes, assessing cellular responses to oxidative stress, and performing drug screening for copper-related therapies. Typical assays include western blotting for ATOX1 and ATP7A/B, RT-qPCR, cellular copper measurement, SOD1 activity, cell viability under oxidative stress, and immunofluorescence for transporter localization. The polyclonal knockout cells provide a reproducible loss-of-function model for mechanistic studies and high-throughput applications. For further technical inquiries, please contact Ascent Research.
